Early laboratory results in mice show the drug PXS-5505 increases survival when combined with chemotherapy in the treatment of an aggressive form of pancreatic cancer.
As COVID finds its equilibrium, infection rates will rise and fall, influenced by seasons, school holidays and new subvariants. Managing the risk is complex and needs to be cost-effective.